Clinical Uses of Botulinum Neurotoxins: Current Indications, Limitations and Future Developments
AbstractBotulinum neurotoxins (BoNTs) cause flaccid paralysis by interfering with vesicle fusion and neurotransmitter release in the neuronal cells. BoNTs are the most widely used therapeutic proteins. BoNT/A was approved by the U.S. FDA to treat strabismus, blepharospam, and hemificial spasm as early as 1989 and then for treatment of cervical dystonia, glabellar facial lines, axillary hyperhidrosis, chronic migraine and for cosmetic use. Due to its high efficacy, longevity of action and satisfactory safety profile, it has been used empirically in a variety of ophthalmological, gastrointestinal, urological, orthopedic, dermatological, secretory, and painful disorders. Currently available BoNT therapies are limited to neuronal indications with the requirement of periodic injections resulting in immune-resistance for some indications. Recent understanding of the structure-function relationship of BoNTs prompted the engineering of novel BoNTs to extend therapeutic interventions in non-neuronal systems and to overcome the immune-resistance issue. Much research still needs to be done to improve and extend the medical uses of BoNTs. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Chen, S. Clinical Uses of Botulinum Neurotoxins: Current Indications, Limitations and Future Developments. Toxins 2012, 4, 913-939.
Chen S. Clinical Uses of Botulinum Neurotoxins: Current Indications, Limitations and Future Developments. Toxins. 2012; 4(10):913-939.Chicago/Turabian Style
Chen, Sheng. 2012. "Clinical Uses of Botulinum Neurotoxins: Current Indications, Limitations and Future Developments." Toxins 4, no. 10: 913-939.